Fluticasone Furoate And Vilanterol Powder
Product Images NDC 66993-135

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Fluticasone Furoate And Vilanterol (NDC 66993-135). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Furoate Chemical Structure (Ff Vil Spl Graphic 01)

Chemical structure of fluticasone furoate, the active ingredient in Fluticasone Furoate and Vilanterol powder for respiratory inhalation.*

FDA Label Image

Vilanterol Chemical Structure (Ff Vil Spl Graphic 02)

Chemical structure of fluticasone furoate and vilanterol showing the molecular arrangement and bonds of the active ingredients in the respiratory powder inhalation product by Prasco Laboratories.*

FDA Label Image

Figure 1 (Ff Vil Spl Graphic 03)

A forest plot displaying pharmacokinetic fold changes with 90% confidence intervals for fluticasone furoate (FF) and vilanterol (VI) across various populations, including severe renal impairment, hepatic impairment (mild to severe), COPD, ethnicity (East Asian), gender (male), and asthma patients older than 65 years. The chart shows changes in AUC and Cmax relative to a reference, along with dosing recommendations such as no dose adjustment or caution.*

FDA Label Image

Figure 2 (Ff Vil Spl Graphic 04)

A pharmacokinetic chart showing fold changes and 90% confidence intervals for fluticasone furoate (FF) and vilanterol (VI) when coadministered with ketoconazole or verapamil. Variables include AUC and Cmax, with recommendations indicating caution for ketoconazole and no dose adjustment for verapamil.*

FDA Label Image

Figure 3 (Ff Vil Spl Graphic 05)

A line graph showing the least squares mean change from baseline in mL over 24 hours for different doses of vilanterol and placebo. The x-axis represents time in hours, and the y-axis shows mean change from baseline. Various symbols represent placebo and vilanterol doses of 3.0, 6.25, 12.5, 25, and 50 mcg.*

FDA Label Image

Figure 3 (Ff Vil Spl Graphic 06)

A line graph showing the least squares (LS) mean change from baseline in mL over time (in hours) following different doses of vilanterol compared to placebo. The graph includes placebo and vilanterol doses of 3.0, 6.25, 12.5, 25, and 50 mcg, illustrating effects on lung function across a 24-hour period.*

FDA Label Image

Figure 4 Day 1 (Ff Vil Spl Graphic 07)

A line graph illustrating mean change from baseline FEV1 (mL) over time since dose (minutes) for several treatments: Fluticasone furoate/Vilanterol ELLIPTA 100/25 mcg, Fluticasone furoate/Vilanterol ELLIPTA 200/25 mcg, Fluticasone furoate 100 mcg, Vilanterol 25 mcg, Fluticasone furoate 200 mcg, and placebo. The graph shows FEV1 improvement trends up to 240 minutes post-dose.*

FDA Label Image

Figure 4 Day 168 (Ff Vil Spl Graphic 08)

A line graph showing mean change from baseline FEV1 (mL) over time since dose (minutes) for several treatments: Fluticasone furoate/vilanterol ELLIPTA 100/25 mcg, Fluticasone furoate/vilanterol ELLIPTA 200/25 mcg, Fluticasone furoate 100 mcg, Vilanterol 25 mcg, Fluticasone furoate 200 mcg, and Placebo. The graph tracks changes up to 240 minutes post-dose, highlighting differences in lung function response among the treatments.*

FDA Label Image

Figure 5 Day 1 (Ff Vil Spl Graphic 09)

A line graph showing the least squares mean change from baseline in mL over time (hours) for different doses of vilanterol compared to placebo. The graph plots changes for placebo and vilanterol doses of 3.0 mcg, 6.25 mcg, 12.5 mcg, 25 mcg, and 50 mcg over a 24-hour period.*

FDA Label Image

Figure 5 Day 28 (Ff Vil Spl Graphic 10)

A line graph depicting the least squares mean change from baseline in mL over 24 hours for different doses of Vilanterol (3.0 mcg, 6.25 mcg, 12.5 mcg, 25 mcg, and 50 mcg) compared to placebo. The x-axis represents time in hours, and the y-axis shows the change in lung function. Multiple dose levels of Vilanterol show varied responses over time, with placebo demonstrating the lowest change.*

FDA Label Image

Figure 6 (Ff Vil Spl Graphic 11)

A forest plot showing the difference from placebo and 95% confidence intervals in milliliters across four clinical trials (Trial 687, Trial 685, Trial 684, Trial 202) for treatments with various doses of Fluticasone Furoate (FF) and Fluticasone Propionate (FP) administered once or twice daily. The x-axis lists treatment doses in micrograms with dosing frequencies, and the y-axis represents the change in lung function volume.*

FDA Label Image

Figure 7 (Ff Vil Spl Graphic 12)

A line graph showing the least squares mean change from baseline (mL) over 24 hours post-dose for Fluticasone Furoate and Vilanterol ELLIPTA 100/25 mcg, Fluticasone Furoate and Vilanterol ELLIPTA 200/25 mcg, and Fluticasone Furoate 100 mcg alone. The x-axis represents time since dose (hours), and the y-axis represents lung function change in mL. Three distinct lines represent the three treatment groups, with varying levels of lung function improvement over time.*

FDA Label Image

Fluticasone Furoate/vilanterol Ellipta Inhaler (Ff Vil Spl Graphic 13)

An exploded illustration showing the packaging components of Fluticasone Furoate and Vilanterol powder for respiratory inhalation. The components include a carton, tray lid, tray, inhaler, desiccant packet, and a patient information leaflet.*

FDA Label Image

Figure A (Ff Vil Spl Graphic 14)

An instructional illustration showing a hand peeling back a foil seal from a rectangular tray containing a respiratory inhalation powder device. The image likely demonstrates how to open the packaging for Fluticasone Furoate and Vilanterol powder inhaler.*

FDA Label Image

Figure B (Ff Vil Spl Graphic 15)

Illustration showing the disposal of a medication blister pack into a trash can. The image depicts proper disposal instructions for used packaging associated with respiratory powder inhalation medication containing fluticasone furoate and vilanterol.*

FDA Label Image

Figure C (Ff Vil Spl Graphic 16)

An instructional diagram of a respiratory inhaler device showing the cover and a dose counter displaying the number 30. The device appears round with a textured grip area and highlights key parts for use or identification.*

FDA Label Image

Figure D (Ff Vil Spl Graphic 17)

An illustration showing the components and usage of a Fluticasone Furoate and Vilanterol powder inhaler. It labels the mouthpiece, air vent, device cover with a 'Click' sound, and a counter displaying the number 29, with fingers demonstrating opening the cover.*

FDA Label Image

Figure E (Ff Vil Spl Graphic 18)

Instructional illustration showing a person holding a respiratory inhaler device near their mouth, demonstrating the correct technique of inhaling the medication with arrows indicating inhalation airflow into the mouth.*

FDA Label Image

Figure F (Ff Vil Spl Graphic 19)

An instructional line drawing showing a person using an inhaler device by placing the mouthpiece in the mouth and holding the inhaler with both hands, demonstrating the proper technique for administering an inhaled powder medication.*

FDA Label Image

Figure G (Ff Vil Spl Graphic 20)

An instructional line drawing showing hands holding an inhalation device. The illustration highlights proper hand placement, cautioning not to block the air vent with fingers during use.*

FDA Label Image

Figure H (Ff Vil Spl Graphic 21)

An instructional illustration showing a person inhaling with a timer icon indicating to hold the breath for 3 to 4 seconds. The image depicts part of the head and shoulders in side profile.*

FDA Label Image

Figure I (Ff Vil Spl Graphic 22)

An instructional illustration showing a person using a respiratory inhalation device. The person is holding the inhaler near their mouth, exhaling, with arrows indicating the direction of breath away from the device, demonstrating the correct technique for inhalation with Fluticasone Furoate and Vilanterol powder inhaler.*

FDA Label Image

Figure J (Ff Vil Spl Graphic 23)

Illustration of a respiratory inhaler device for Fluticasone Furoate and Vilanterol powder, showing the mouthpiece cover being lifted open with an arrow indicating the direction. The device also features a dose counter displaying the number 29.*

FDA Label Image

Figure K (Ff Vil Spl Graphic 24)

Illustration showing a person rinsing their mouth by spitting water into a sink with a faucet and a glass of water on the counter, likely demonstrating a post-inhalation oral hygiene step.*

FDA Label Image

Figure L (Ff Vil Spl Graphic 25)

An illustration of a respiratory inhaler device for Fluticasone Furoate and Vilanterol powder. The device has a curved shape with a protective cap on top. A window on the front shows a red indicator with the number 9, likely representing remaining doses or usage status.*

FDA Label Image

Fluticasone Furoate-vilanterol Ellipta 100 Mcg-25mcg Carton (Ff Vil Spl Graphic 26)

Packaging label for Fluticasone Furoate/Vilanterol ELLIPTA Inhalation Powder, 100 mcg/25 mcg strength. The label shows the inhaler device and indicates it contains 30 doses per inhaler (60 blisters total). Labeler is Prasco Laboratories, with NDC 66993-135-97. The product is for oral inhalation only and prescription use.*

FDA Label Image

Fluticasone Furoate-vilanterol Ellipta 200mcg-25mcg Carton (Ff Vil Spl Graphic 27)

Label for Fluticasone Furoate/Vilanterol ELLIPTA Inhalation Powder by Prasco Laboratories, strength 200 mcg/25 mcg. The label shows the inhaler device and states the package contains 1 ELLIPTA Inhaler with 30 doses (60 blisters total). It includes usage instructions and dosage form as powder for oral inhalation only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.